Keyphrases
Randomized Controlled Trial
61%
Hospitalized Patients
60%
Confidence Interval
57%
Recurrent Urinary Tract Infections (rUTIs)
50%
Colistin
48%
Risk Factors
48%
COVID-19
46%
BNT162b2 Vaccine
43%
Clinical Outcomes
40%
Odds Ratio
39%
Prospective Cohort Study
38%
Multidrug-resistant Gram-negative Bacteria
38%
Systematic Meta-analysis
35%
Clostridium Difficile Infection
31%
Bacteremia
31%
Retrospective Cohort Study
27%
Hospitalization
27%
Israel
26%
Vaccination
25%
Severe Infection
24%
Immunogenicity
23%
30-day Mortality
23%
Urinary Tract Infection
23%
Meta-analysis of Randomized Controlled Trials
23%
Treatment Failure
21%
Risk Ratio
21%
Meta-analysis
21%
Clinical Failure
20%
Vancomycin
20%
Readmission
20%
Empiric Antibiotics
20%
Cancer Patients
18%
External Validity
18%
Retrospective Observational Study
18%
Monotherapy
17%
Sepsis Treatment
17%
Meropenem
17%
Hydroxymethylglutaryl-CoA Reductase Inhibitors/statins
17%
Antibiotics
17%
Adverse Events
16%
Vaccine Dose
16%
Influenza Vaccination
16%
Combination Therapy
15%
Gram-negative Bacteremia
15%
Community-acquired Pneumonia
14%
Bloodstream Infection
14%
Multidrug Resistance
14%
Statins
14%
Pneumonia
13%
Carbapenem-resistant Acinetobacter Baumannii
13%
Pharmacology, Toxicology and Pharmaceutical Science
Infection
85%
Randomized Controlled Trial
78%
Antibiotics
58%
Carbapenem
53%
Colistimethate
48%
Urinary Tract Infection
39%
SARS Coronavirus
34%
Malignant Neoplasm
33%
Prospective Cohort Study
31%
Antibiotic Agent
31%
Cohort Study
30%
Retrospective Study
29%
Vaccination Policy
26%
Gram Negative Bacterium
25%
Meropenem
25%
Clostridium Difficile Infection
23%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
23%
Adverse Event
22%
Infectious Agent
21%
Gram Negative Sepsis
19%
Vancomycin
19%
Sepsis
18%
Immunogenicity
17%
Bacteremia
17%
mRNA Vaccine
17%
Oxidoreductase
17%
Methicillin Resistant Staphylococcus Aureus Infection
17%
Observational Study
16%
Monotherapy
16%
Community Acquired Pneumonia
14%
Combination Therapy
13%
Disease
13%
Gram Negative Infection
12%
Cotrimoxazole
12%
Comorbidity
12%
Antibiotic Therapy
11%
Live Attenuated Influenza Vaccine
11%
Candidemia
11%
Randomized Clinical Trial
11%
Immunoglobulin G Antibody
11%
Quinolone Derivative
10%
Acinetobacter Baumannii
10%
All Cause Mortality
9%
Fosfomycin
9%
Chemotherapy
8%
Respiratory Tract Infection
8%
Macrolide
8%
Diabetes Mellitus
8%
Nitrofurantoin
8%
Pharmacokinetics
8%
Medicine and Dentistry
Infection
100%
Randomized Controlled Trial
51%
Urinary Tract Infection
51%
Malignant Neoplasm
42%
Antibiotics
42%
Carbapenem
36%
Antibiotic Therapy
33%
Odds Ratio
31%
Retrospective Study
30%
Retrospective Cohort Study
25%
Colistimethate
25%
Prospective Cohort Study
24%
Gram-Negative Bacteria
24%
Severe Acute Respiratory Syndrome Coronavirus 2
24%
Observational Study
23%
Pathogen
21%
Bloodstream Infection
19%
COVID-19
19%
Clostridium Difficile Infection
17%
Influenza Vaccination
17%
Cancer
14%
Meropenem
13%
Meta-Analysis
13%
Arm
12%
Adverse Event
12%
Multidrug-Resistant Gram-Negative Bacteria
12%
Systematic Review
11%
Candidemia
11%
Internal Medicine
11%
Randomized Clinical Trial
11%
Bacteremia
10%
Mortality Rate
10%
Influenza Vaccine
10%
Cohort Analysis
9%
Symptom
9%
Gram Negative Sepsis
9%
Diarrhea
9%
Multidrug Resistance
9%
Fosfomycin
8%
Omicron Coronavirus Variant
8%
Monotherapy
8%
Antiinfective Agent
8%
Acinetobacter Baumannii
8%
Disease
8%
Nitrofurantoin
8%
Urinary System
8%
Predictive Factor
8%
Subgroup Analysis
8%
Combination Therapy
7%
Acinetobacter Infection
7%